Estée Lauder Companies
EL
$102.30
-1.05%
The Estée Lauder Companies Inc. is a global leader in the prestige beauty market, offering a diverse portfolio of skin care, makeup, fragrance, and hair care products under iconic brands such as Estée Lauder, Clinique, M.A.C, La Mer, and Jo Malone London. The company operates in over 150 countries, with a strong presence in department stores, travel retail, and e-commerce, positioning it as a dominant player in the premium beauty segment. Currently, the stock is in the spotlight as investors debate the success of its turnaround strategy, which has shown early signs of accelerating sales and margin expansion, while the company recently walked away from merger talks with Puig to pursue an independent path. The narrative centers on whether Estée Lauder can sustain its recovery in a competitive and evolving beauty landscape.…
EL
Estée Lauder Companies
$102.30
Related headlines
Investment Opinion: Should I buy EL Today?
We rate EL as a Buy, driven by the early success of its turnaround, with revenue growth of 4.56% and expanding margins. The consensus analyst rating is 'Buy' with an average target price of $106.46, implying ~3% upside, but the high target of $127 suggests potential for 22.8% upside if execution is flawless. The stock is attractively valued on a forward basis, with a forward PE of 26.5x, which is reasonable for a company expected to see significant earnings growth.
Sign up to view all
EL 12-Month Price Forecast
The AI assessment is bullish with medium confidence, reflecting the positive momentum in revenue and margins, but tempered by the high leverage and execution risks. The forward PE of 26.5x suggests the market is pricing in a significant earnings recovery, which is plausible given the turnaround progress. However, the stock's beta of 1.246 and underperformance relative to the market over the past year indicate that sentiment could shift quickly. I would upgrade to high confidence if revenue growth accelerates above 6% and margins expand as projected, or downgrade to neutral if growth decelerates below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $106.46 and implied upside of +4.1% versus the current price.
Average Target
$106.46
0 analysts
Implied Upside
+4.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
The wide range between the low and high targets reflects significant uncertainty about the company's future. The high target of $127 assumes successful execution of the turnaround, with accelerating growth and margin expansion, while the low target of $70 prices in a prolonged recovery or further deterioration in the competitive landscape. Recent institutional ratings have been largely stable, with no major upgrades or downgrades, indicating that analysts are waiting for more evidence of sustained improvement before adjusting their outlooks.
Bulls vs Bears: EL Investment Factors
The bull case is currently stronger, supported by concrete evidence of revenue growth, margin expansion, and a robust stock rebound. However, the bear case highlights the high valuation and leverage, which amplify downside risk if the turnaround stumbles. The central tension is whether the forward PE of 26.5x is justified by the expected earnings recovery; if growth accelerates and margins expand as projected, the stock could re-rate higher, but any disappointment could lead to a sharp correction. Overall, the evidence leans bullish, but the risk-reward is balanced given the execution uncertainty.
Bullish
- Return to Revenue Growth: Q3 FY2026 revenue grew 4.56% YoY to $3.712 billion, marking a return to growth after stagnation. This is a key sign that the turnaround strategy is gaining traction, with skin care and makeup (79% of revenue) leading the recovery.
- Margin Expansion Underway: Gross margin improved to 75.5% (TTM) from 71.0% in Q3 FY2026, and operating margin rose to 5.18% (TTM) from 2.35% in Q4 FY2025. This demonstrates the company's ability to expand profitability as it optimizes costs and mix.
- Strong Rebound from 52-Week Low: The stock has surged 56.1% from its 52-week low of $66.22 to $103.39, reflecting growing investor confidence in the turnaround. The recovery is supported by a 22.9% gain in the last month alone, indicating strong momentum.
- Positive Analyst Sentiment: With a consensus 'Buy' rating and an average target price of $106.46, analysts see ~3% upside from the current price. The high target of $127 implies a 22.8% upside, suggesting that successful execution could lead to significant re-rating.
Bearish
- Elevated Trailing Valuation: The trailing PE of 157.9x is extremely high, reflecting depressed earnings (TTM net income of only $89 million). This leaves little room for error; any earnings miss could trigger a sharp de-rating.
- High Debt-to-Equity Ratio: Debt-to-equity stands at 2.43x, indicating significant leverage. With interest expenses of $82 million in Q3 FY2026, the company is exposed to rising interest rates, which could pressure margins and earnings.
- Asia-Pacific Weakness: The Asia-Pacific region, which accounts for 32% of revenue, has been a drag on overall performance. Continued softness in China and travel retail could limit growth and delay the recovery.
- Negative Relative Strength vs. Market: Over the past year, EL has underperformed the S&P 500 by 5.9 percentage points (12.66% vs. 18.56%). This suggests that the market remains skeptical about the sustainability of the turnaround.
EL Technical Analysis
The stock is in a clear recovery phase, having rebounded sharply from its 52-week low of $66.22 to a current price of $103.39, representing a 56.1% gain from that low. Over the past year, the stock is up 12.66%, but it remains well below its 52-week high of $121.64, trading at 85% of that high. This positioning suggests the stock is recovering from a significant drawdown (max drawdown of -43.79%) but still has room to reclaim prior highs, indicating a potential value opportunity if the turnaround continues.
Beta
1.25
1.25x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+11.5%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | +21.9% | +2.7% |
| 3m | +22.6% | +1.0% |
| 6m | +3.1% | +12.0% |
| 1y | +11.5% | +18.9% |
| ytd | -4.2% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue in the most recent quarter (Q3 FY2026, ended March 31, 2026) was $3.712 billion, up 4.56% year-over-year, marking a return to growth after a period of stagnation. The growth was driven by strong performance in skin care ($1.856 billion) and makeup ($1.072 billion), which together account for 79% of total revenue. However, the growth rate is modest compared to historical levels, and the company faces challenges in the Asia-Pacific region, which has been a drag on overall performance.
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Given that net income is positive (TTM net income of $89 million), the PE ratio is the primary valuation metric. The trailing PE is 157.9x, while the forward PE is 26.49x, indicating that the market expects a significant earnings recovery. The gap between trailing and forward PE suggests that the market is pricing in a substantial improvement in profitability, which is consistent with the company's turnaround narrative.
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 28x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
40.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a debt-to-equity ratio of 2.43x and interest expenses of $82 million in Q3 FY2026. The company's net margin is razor-thin at 1.2% (TTM), leaving little cushion for operational hiccups. While free cash flow is positive at $1.285 billion, the high leverage and low profitability make the stock vulnerable to earnings shocks. Additionally, the trailing PE of 157.9x implies that the market is pricing in a massive earnings recovery; if that recovery is delayed, the stock could face severe de-rating.